TNFRSF18 and neoplasm: Another work by Cohen et al. studies tumor-specific CD8+ cells after adoptive transfer and demonstrates that anti-GITR treatment augments [21] their activation, proliferation, and accumulation in the tumor site leading to a long-term survival [71].